Equillium, Inc. cotiza a 1.32 USD y tiene una capitalización bursátil de $84M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation …
| Periodo | 2026-11 | 2026-11 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.06 | $-0.04 |
| Estimado | $-0.22 | $-0.05 | $-0.04 | $-0.06 |
| Sorpresa | — | — | -50.0% | +33.3% |
| Métrica | EQ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -78.3% | -40.4% | -37.9% |
| ROA | -70.2% | -32.0% | -38.2% |
| Current Ratio | 10.58 | 2.84 | +7.74 |
| Debt / Equity | — | 0.28 | — |